William Blair Reiterates Neutral Rating for Intellia Therapeutics (NASDAQ:NTLA)

Intellia Therapeutics (NASDAQ:NTLA)‘s stock had its “neutral” rating reaffirmed by William Blair in a research report issued on Monday,RTT News reports. They presently have a $14.00 price target on the stock. William Blair’s price objective suggests a potential upside of 0.65% from the stock’s current price.

A number of other equities analysts have also recently issued reports on NTLA. StockNews.com upgraded shares of Intellia Therapeutics to a “sell” rating in a research report on Friday, November 8th. Robert W. Baird decreased their target price on shares of Intellia Therapeutics from $24.00 to $18.00 and set a “neutral” rating for the company in a research note on Friday, October 25th. Stifel Nicolaus decreased their target price on shares of Intellia Therapeutics from $80.00 to $64.00 and set a “buy” rating for the company in a report on Wednesday, September 11th. JPMorgan Chase & Co. reduced their price objective on Intellia Therapeutics from $61.00 to $55.00 and set an “overweight” rating for the company in a report on Monday, August 12th. Finally, Wedbush reiterated a “neutral” rating and set a $14.00 price objective on shares of Intellia Therapeutics in a research report on Thursday, November 7th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Intellia Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $52.80.

Intellia Therapeutics Trading Down 0.4 %

Shares of Intellia Therapeutics stock traded down $0.06 during trading on Monday, hitting $13.91. The stock had a trading volume of 2,678,379 shares, compared to its average volume of 1,685,642. The firm has a market cap of $1.42 billion, a price-to-earnings ratio of -2.58 and a beta of 1.81. Intellia Therapeutics has a 12 month low of $13.54 and a 12 month high of $34.87. The business’s 50-day moving average is $18.64 and its 200 day moving average is $22.04.

Intellia Therapeutics (NASDAQ:NTLA) last released its quarterly earnings results on Thursday, November 7th. The company reported ($1.34) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.37) by $0.03. The firm had revenue of $9.10 million for the quarter, compared to analysts’ expectations of $8.28 million. The company’s revenue for the quarter was down 24.1% on a year-over-year basis. During the same quarter in the previous year, the business earned ($1.38) EPS. As a group, equities analysts expect that Intellia Therapeutics will post -5.13 EPS for the current year.

Insider Activity

In other Intellia Therapeutics news, CAO Michael P. Dube sold 2,012 shares of the company’s stock in a transaction that occurred on Wednesday, October 2nd. The stock was sold at an average price of $19.01, for a total transaction of $38,248.12. Following the sale, the chief accounting officer now directly owns 47,012 shares in the company, valued at $893,698.12. This represents a 4.10 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 3.20% of the company’s stock.

Institutional Investors Weigh In On Intellia Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. SG Americas Securities LLC purchased a new stake in shares of Intellia Therapeutics in the first quarter valued at about $160,000. Swiss National Bank grew its position in Intellia Therapeutics by 1.3% in the first quarter. Swiss National Bank now owns 167,900 shares of the company’s stock worth $4,619,000 after acquiring an additional 2,200 shares during the period. ProShare Advisors LLC lifted its stake in shares of Intellia Therapeutics by 11.9% in the 1st quarter. ProShare Advisors LLC now owns 23,235 shares of the company’s stock valued at $639,000 after purchasing an additional 2,466 shares during the last quarter. Vanguard Group Inc. boosted its position in shares of Intellia Therapeutics by 8.9% during the 1st quarter. Vanguard Group Inc. now owns 9,093,712 shares of the company’s stock worth $250,168,000 after purchasing an additional 746,263 shares during the period. Finally, EntryPoint Capital LLC raised its position in Intellia Therapeutics by 61.1% in the 1st quarter. EntryPoint Capital LLC now owns 4,122 shares of the company’s stock valued at $113,000 after purchasing an additional 1,563 shares in the last quarter. Hedge funds and other institutional investors own 88.77% of the company’s stock.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.